Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

BeiGene has struck a $150 million deal to license a cancer candidate from CSPC Zhongqi Pharmaceutical Technology, positioning ...

Medtronic reported that a patient has completed the first procedure with the latest version of its ingestible camera, used to ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Billion-dollar biotech startup Xaira is expanding its C-suite with some top pharma talent. After wrapping up a 16-year tenure ...

Danish pharma company Bavarian Nordic is shutting down its U.S.-based R&D site in San Diego and laying off all 48 employees ...

The FDA has opened up the use of Johnson & Johnson’s miniaturized heart pumps to certain pediatric patients, including those ...

In LAVA-1207’s absence, Lava will now be bumping up LAVA-1266, which is due to enter the clinic before the end of the year.